Larimar Therapeutics
LRMR
65 hedge funds and large institutions have $120M invested in Larimar Therapeutics in 2023 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 25 increasing their positions, 13 reducing their positions, and 17 closing their positions.
350% more call options, than puts
Call options by funds: $27K | Put options by funds: $6K
92% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 13
1.38% more ownership
Funds ownership: 88.82% → 90.2% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less funds holding
Funds holding: 68 → 65 (-3)
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
31% less capital invested
Capital invested by funds: $174M → $120M (-$54M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.55M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
+$3.17M |
| 3 |
CA
CHI Advisors
New York
|
+$2.73M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$2.04M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$10.3M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$4.08M |
| 3 |
JP Morgan Chase
New York
|
-$2.49M |
| 4 |
Millennium Management
New York
|
-$1.28M |
| 5 |
FAM
Fred Alger Management
New York
|
-$778K |
LRMR Hedge Fund Activity: Q2 2023 in Review
65 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q2 2023, worth a combined $120M — down 31% from $174M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of LRMR and 14 opened new positions — a net loss of 3 holders — while 13 trimmed existing stakes and 25 added.
The largest buyer was BlackRock, adding an estimated $4.55M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $10.3M sold.
- 65 institutional investors held Larimar Therapeutics (LRMR) as of Q2 2023, down from 68 in Q1 2023.
- Funds reported $120M of Larimar Therapeutics stock for Q2 2023, down 31% quarter-over-quarter.
- 14 funds opened new Larimar Therapeutics positions in Q2 2023 and 17 closed out, a net change of -3 holders.
- The largest Larimar Therapeutics buyer in Q2 2023 was BlackRock, an estimated $4.55M added.
- The largest Larimar Therapeutics seller in Q2 2023 was Perceptive Advisors, an estimated $10.3M sold.
Based on aggregated 13F filings for Q2 2023.